Drug Trials Snapshots: SOHONOS (palovarotene)

Fibrodysplasia ossificans progressiva (FOP) is a rare genetic disease in which there is abnormal growth of bone tissue (heterotopic ossification or HO) within muscles, tendons, and other soft tissues, which restricts mobility and can be disabling. SOHONOS is a retinoid drug that is indicated to reduce the amount (measured as volume) of new HO in patients with FOP who are aged 8 years and older for females and 10 years and older for males. https://www.fda.gov/drugs/drug-approvals-and-databases/drug-trials-snapshots-sohonos